title: [Treatment of low-pressure vascular malformations by injection of Ethibloc. Study of 19 cases and analysis of complications].
abstract: We retrospectively studied the cases of 19 patients suffering from low flow vascular malformations who were treated with Ethibloc sclerotherapy. Out of 10 venous angiomas, 5 entirely disappeared, 3 considerably decreased and 2 remained unaltered. Out of 7 cystic lymphangiomas, 7 were completely cured and in the 2 other cases, outcome was quite good. Post-treatment complications consisted in a local inflammatory reaction. This reaction occurred immediately and disappeared within a few days without after-effects. It materialized as an Ethibloc exteriorization among 5 patients suffering from venous angiomas and 3 patients suffering from lymphangiomas and as an inflammatory lump for 2 venous angiomas carriers and for 4 lymphangiomas carriers. This lump was located at the puncture point of the product and it was due to some Ethibloc residue. Fourteen of these local reactions spontaneously decreased; 5 of them required a surgical operation but in all cases, after-effects were minor. These satisfactory results (volume decreasing in 90% of the malformations) as well as the mildness of the side effects encourage to use Ethibloc in the treatment of low flow vascular malformations. In our experience, Ethibloc is particularly appropriate for the treatment of large lymphangiomas.
authors: Service de stomatologie, de Chirurgie Maxillo-Faciale et Chirurgie Plastique de la face, Centre Hospitalier Lyon-Sud, Pierre-Bénite.
authors: A V
authors: AV
authors: Baud
authors: P
authors: P
authors: Breton
authors: L
authors: L
authors: Guibaud
authors: M
authors: M
authors: Freidel
mesh_terms: D000328:Adult; D001165:Arteriovenous Malformations / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003973:Diatrizoate / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005227:Fatty Acids / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006099:Granuloma / Q000209:etiology; D006258:Head and Neck Neoplasms / Q000628:therapy; D006391:Hemangioma / Q000628:therapy; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008175:Lung Neoplasms / Q000628:therapy; D018191:Lymphangioma, Cystic / Q000628:therapy*; D008297:Male; D011409:Propylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D012597:Sclerosing Solutions / Q000009:adverse effects / Q000627:therapeutic use*; D015911:Sclerotherapy / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome; D015028:Zein / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D005227:Fatty Acids; D011409:Propylene Glycols; D012597:Sclerosing Solutions; D003973:Diatrizoate; D015028:Zein; C020481:alcoholic prolamine solution